The USPSTF Recommendation on Thyroid Cancer Screening

This Editorial reviews thyroid cancer diagnosis and mortality in light of the latest USPSTF recommendation against screening for the disease.

http://ift.tt/2qYx2mX

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Conditions:   Advanced Hepatocellular Carcinoma (HCC);   Cholangiocarcinoma;   Esophageal Cancer;   Nasopharyngeal Cancer;   Serous Ovarian Cancer;   Solid Tumor Malignancies With Documented FGF19/FGFR4 Alteration
Intervention:   Drug: INCB062079
Sponsor:   Incyte Corporation
Not yet recruiting - verified May 2017

http://ift.tt/2qOdCE0

Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)

Condition:   Malignant Neoplasms of Lip Oral Cavity and Pharynx
Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Behavioral: Questionnaire;   Procedure: Surgery;   Drug: Chemotherapy;   Radiation: Radiation Therapy
Sponsors:   M.D. Anderson Cancer Center;   AstraZeneca;   Stiefel, a GSK Company
Not yet recruiting - verified May 2017

http://ift.tt/2prqSJS

Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)

Conditions:   Metastatic Colorectal Cancer;   Metastatic Head and Neck Cancer
Intervention:   Other: Magnesium-rich mineral water (Rozana)
Sponsors:   Weprom;   Neptune
Not yet recruiting - verified May 2017

http://ift.tt/2qOdCnu

Using Magnetic Resonance Imaging (MRI) to Assess Normal Tissue and Tumor Response to Radiation Therapy

Condition:   Head and Neck Cancer
Interventions:   Procedure: Magnetic Resonance Imaging (MRI);   Behavioral: Questionnaires
Sponsors:   M.D. Anderson Cancer Center;   National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified May 2017

http://ift.tt/2prqRFO

Adverse events associated with discontinuation of the biologics/classic systemic treatments of moderate-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm

Abstract

Background

Little is known about the adverse events (AEs) that lead to suspension of systemic treatments of psoriasis in clinical practice.

Objective

The study aimed to investigate to AEs associated with discontinuation of systemic therapy in patients with psoriasis in a clinical setting (Biobadaderm).

Materials and methods

Multicenter, prospective, cohort study of patients with moderate-to-severe plaque psoriasis receiving systemic therapies from January 2008 to November 2015, in 12 hospitals in Spain. The incidence rate (IR) was used to compare biologics and classic systemic therapies.

Results

A total of 4218 courses of treatment were used in 1938 patients. A total of 447 (11%) treatments were discontinued due to AEs. The IR of AE associated with discontinuation of systemic therapies was 13 events/100 patient-years (PY) (95%CI:12.14-13.93), 9.34 events/100PY (95% CI:8.44-10.33) for biologics and 19.67 (95%CI:17.9-21.6) events/100PY for classics (p< 0.001). Of 810 discontinuation-related AEs, 117 (14%) were serious. The highest IRs were for cyclosporine [49.18/100PY (95%CI:41.91-57.72)] and infliximab [26.52/100PY (95%CI:20.98-33.51). Ustekinumab presented the lowest IR (2.6/100PY (95%CI:1.83-3.69).

Limitations

Observational study with potential selection bias.

Conclusion

Biologic therapies are associated with a lower rate of discontinuation-related AEs than are classic therapies in real clinical practice. Ustekinumab showed the lowest incidence.

This article is protected by copyright. All rights reserved.

http://ift.tt/2qXW31x

Multimorbidity in Bullous Pemphigoid: a case-control analysis of BP patients with age and gender matched controls

Abstract

Background

Bullous Pemphigoid (BP) is the most common autoimmune blistering disease in the elderly and is associated with increased mortality. The extent of multimorbidity in patients with BP and its impact on survival is unclear.

Objectives

To describe the extent and spectrum of multimorbidity in patients with BP and to ascertain its impact on survival.

Methodology

This was a case-control study conducted in the setting of an academic medical centre. Cases defined as newly diagnosed BP patients referred to the inpatient dermatology service between 2005 and 2014. For every case, 3 age- and gender-matched controls were randomly selected. Retrospective review of medical records was performed. Univariate and multivariate comparisons of cases and controls were performed using conditional logistic regression.

Results

105 cases and 315 controls were included in this study. 88 cases (84%) were multi-morbid (≥ 2 chronic diseases) as compared to 205 controls (65%) (p < 0.001), while the mean no. of comorbid conditions was 3.2 +/- 1.6 in cases compared to 2.4 +/- 1.6 in controls (p < 0.001). 43% of cases had ≥ 4 comorbidities compared to 27% in controls (p = 0.003). On multivariate analysis (adjusting for age, gender and comorbidities), neurological disease OR 10.93 (CI: 5.74, 20.79), hypertension OR 2.38 (1.18, 4.77) were positively associated with BP. Charlson comorbidity index was 6.0 +/- 2.5 in cases compared to 5.0 +/- 2.1 in controls (p = 0.002), and the 1-year mortality of cases and controls were 21.0% and 17.8% respectively.

Conclusion

Our study has shown that a significant proportion of patients with BP are multi-morbid, and individually has a higher no. of comorbidities compared to matched controls. Disease burden and multimorbidity may well impact the prognosis of patients with BP.

This article is protected by copyright. All rights reserved.

http://ift.tt/2qmU89E